01:35 PM EDT, 04/12/2024 (MT Newswires) -- Lipocine ( LPCN ) said Thursday that a phase 2 trial of LPCN 2401 showed improved body composition in participants with obesity.

LPCN 2401 demonstrated increased lean mass by 4.4% and reduced fat mass by 6.7%. It also showed decreased android fat by 4.1% and increased bone mineral content by 2.8%, the company said.

LPCN 2401 was also well-tolerated and adverse events were comparable to placebo, Lipocine ( LPCN ) said.

Price: 5.97, Change: -0.44, Percent Change: -6.86